Karyopharm Therapeutics Inc.'s KPTIshares increased more than 6% on Apr 10 after the company announced that its oral selective inhibitor of nuclear export (SINE) compound, selinexor (KPT-330), has been granted a fast track designation by the FDA.
Karyopharm's Myeloma Candidate Gets Fast Track Designation
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться